Kah Whye Peng

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Strategies for targeting therapeutic gene delivery
    K W Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Mol Med Today 5:448-53. 1999
  2. ncbi request reprint Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice
    Kah Whye Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hum Gene Ther 14:1565-77. 2003
  3. ncbi request reprint Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA
    Blood 101:2557-62. 2003
  4. ncbi request reprint Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme
    Loi K Phuong
    Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 63:2462-9. 2003
  5. ncbi request reprint Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
    Cory Allen
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:11840-50. 2006
  6. ncbi request reprint Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:1868-75. 2006
  7. ncbi request reprint Antibody-targeted cell fusion
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Foundation, 200 First St SW, Rochester, Minnesota 55905, USA
    Nat Biotechnol 22:331-6. 2004
  8. ncbi request reprint Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma
    Boris Blechacz
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 44:1465-77. 2006
  9. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
  10. ncbi request reprint Reengineering paramyxovirus tropism
    Elizabeth M Hadac
    Molecular Medicine Program, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Virology 329:217-25. 2004

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Strategies for targeting therapeutic gene delivery
    K W Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Mol Med Today 5:448-53. 1999
    ..This review summarizes recent strategies to alter vector tropism for targeted gene delivery...
  2. ncbi request reprint Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice
    Kah Whye Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hum Gene Ther 14:1565-77. 2003
    ....
  3. ncbi request reprint Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA
    Blood 101:2557-62. 2003
    ..Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group...
  4. ncbi request reprint Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme
    Loi K Phuong
    Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 63:2462-9. 2003
    ..c. and orthotopic U87 animal models. Monitoring CEA levels in the serum can serve as a low-risk method of detecting viral gene expression during treatment, and could allow dose optimization and individualization of treatment...
  5. ncbi request reprint Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
    Cory Allen
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:11840-50. 2006
    ....
  6. ncbi request reprint Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:1868-75. 2006
    ..Because of the unfavorable replication kinetics of measles viruses expressing both CEA and NIS, we explored the feasibility of combining MV-CEA with MV-NIS for comprehensive virotherapy monitoring in ovarian cancer...
  7. ncbi request reprint Antibody-targeted cell fusion
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Foundation, 200 First St SW, Rochester, Minnesota 55905, USA
    Nat Biotechnol 22:331-6. 2004
    ....
  8. ncbi request reprint Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma
    Boris Blechacz
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 44:1465-77. 2006
    ..MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner...
  9. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  10. ncbi request reprint Reengineering paramyxovirus tropism
    Elizabeth M Hadac
    Molecular Medicine Program, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Virology 329:217-25. 2004
    ..We conclude that paramyxoviruses have a remarkably flexible and adaptable entry mechanism...
  11. ncbi request reprint Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer
    Rae Myers
    Toxicology Core, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Gene Ther 12:593-9. 2005
    ..All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents...
  12. ncbi request reprint High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus
    Bambi D Anderson
    Molecular Medicine Program, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 64:4919-26. 2004
    ..Discrimination between high and low CD46 receptor density provides a compelling basis for the oncolytic specificity of MV-Edm and establishes MV-Edm as a promising CD46-targeted cancer therapeutic agent...
  13. pmc Engineering oncolytic measles virus to circumvent the intracellular innate immune response
    Iana Haralambieva
    1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Mol Ther 15:588-97. 2007
    ..These results indicate that oncolytic viruses are subject to control by the innate immune defenses of human tumor cells and may therefore be more effective if their natural ability to combat innate immunity is maintained...
  14. ncbi request reprint Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota, USA
    Nat Med 8:527-31. 2002
    ..Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy...
  15. ncbi request reprint Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas
    Georgia Paraskevakou
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mol Ther 15:677-86. 2007
    ....
  16. pmc Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:7246-55. 2009
    ..Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used...
  17. ncbi request reprint Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  18. ncbi request reprint The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:6170-8. 2006
    ..To minimize potential toxicity due to measles virus-associated immunosuppression and infection of nontarget tissues, we sought to develop an ovarian cancer exclusive fully retargeted measles virus...
  19. ncbi request reprint Interaction of measles virus vectors with Auger electron emitting radioisotopes
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 337:22-9. 2005
    ..MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo...
  20. pmc Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins
    Camilo Ayala-Breton
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 23:484-91. 2012
    ....
  21. pmc Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma
    Kah Whye Peng
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 84:401-7. 2009
    ..Thus, TAM are a universal stromal component of the plasmacytomas of myeloma patients and may offer a promising new target for therapeutic exploitation. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  22. ncbi request reprint Oncolytic measles virus targets high CD46 expression on multiple myeloma cells
    Hooi Tin Ong
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Exp Hematol 34:713-20. 2006
    ..In this study, we investigated the potential of CD46 as a target for MM therapy and correlated surface levels of CD46 on MM cells with their susceptibility to MV-induced cytopathic effects...
  23. pmc PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice
    Mulu Z Tesfay
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 87:3752-9. 2013
    ..We are currently investigating if this increase in PEGylated VSV circulating half-life can translate to increased virus delivery and better efficacy in mouse models of multiple myeloma...
  24. pmc Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Mol Ther 20:1139-47. 2012
    ..These data suggest that potent immunomodulators of bacterial origin, such as H. pylori NAP, can enhance the antitumor effect of oncolytic viruses and support the feasibility and potential of a combined viroimmunotherapy approach...
  25. pmc Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer
    Chunsheng Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Prostate 69:1128-41. 2009
    ....
  26. pmc Enhancing cytokine-induced killer cell therapy of multiple myeloma
    Chunsheng Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Exp Hematol 41:508-17. 2013
    ..This study demonstrates the potential of CIK against myeloma and that the combination of virotherapy with radiation could be used to further enhance therapeutic outcome using CIK cells...
  27. pmc Oncolytic measles virus strains in the treatment of gliomas
    Cory Allen
    Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Biol Ther 8:213-20. 2008
    ..Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy...
  28. pmc Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 11:20. 2013
    ..In preparation for a clinical trial to use MSC as MV carriers, we obtained cells from ovarian cancer patients and evaluated feasibility and safety of this approach...
  29. pmc Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
    Apollina Goel
    Molecular Medicine Program, College of Medicine, Mayo Clinic, Guggenheim 1833, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:4063-70. 2006
    ..PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the efficacy of skeletal-targeted radiotherapy in multiple myeloma...
  30. pmc Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
    ..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
  31. pmc Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry
    Matthew K Ennis
    Department of Molecular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 84:10913-7. 2010
    ..We show that after binding of MV to its receptor, H-F dissociation is required for productive infection...
  32. pmc Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo
    Hooi Tin Ong
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 17:1012-21. 2009
    ..To our knowledge, this is the first report demonstrating that oncolytic MVs can be engineered to target the lumenal endothelial surface of newly formed blood vessels when administered intravenously in living animals...
  33. pmc Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome
    Linh Pham
    Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Gene Med 11:197-206. 2009
    ....
  34. pmc Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers
    Chunsheng Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 18:1155-64. 2010
    ..Hence, we demonstrate for the first time that systemically administered cells can serve as MV carriers and prolonged survival of mice with pre-existing antimeasles antibodies...
  35. pmc Affinity thresholds for membrane fusion triggering by viral glycoproteins
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 81:13149-57. 2007
    ..For a given cell surface receptor density, there is an affinity threshold above which cell-cell fusion proceeds efficiently. Suprathreshold affinities do not further enhance the efficiency of membrane fusion...
  36. pmc Long-term infection and vertical transmission of a gammaretrovirus in a foreign host species
    Toshie Sakuma
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e29682. 2012
    ..Our results therefore demonstrate long-term asymptomatic infection, low incidence of vertical transmission and limited evolution of XMRV upon transspecies infection of a permissive new host, Mus pahari...
  37. pmc Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates
    Nathan Jenks
    Toxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 21:451-62. 2010
    ..On the basis of these studies, we will be proposing a cautious approach to dose escalation in a phase I clinical trial among patients with HCC...
  38. doi request reprint Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer
    Yu Ping Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA
    Gynecol Oncol 132:194-202. 2014
    ....
  39. pmc Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy
    Hongtao Li
    Mayo Clinic Department of Molecular Medicine, Rochester, MN 55905, USA
    Hum Gene Ther 23:295-301. 2012
    ..MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN...
  40. ncbi request reprint Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas
    Cory Allen
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Gene Med 6:1216-27. 2004
    ..Given the high frequency of MMP overexpression in gliomas, AdM40 represents a potentially promising agent in the gene therapy of these tumors...
  41. pmc Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread
    Camilo Ayala-Breton
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 21:1930-7. 2013
    ..Its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51...
  42. ncbi request reprint Primer on medical genomics. Part X: Gene therapy
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1370-83. 2003
    ..This review should serve as an introduction to the subject of gene therapy for clinician investigators, physicians and medical scientists in training, practicing clinicians, and other students of medicine...
  43. pmc Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters
    Kent Bailey
    Department of Biomedical STatistics and Informatics, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e73759. 2013
    ..The new model provides a useful and flexible tool for virotherapy protocol optimization. ..
  44. pmc Oncolytic virotherapy
    Stephen J Russell
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Biotechnol 30:658-70. 2012
    ....
  45. pmc Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands
    Arun Ammayappan
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 87:13543-55. 2013
    ..This study provides a rational foundation for the future development of fully retargeted oncolytic VSVs. ..
  46. pmc Viruses as anticancer drugs
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Trends Pharmacol Sci 28:326-33. 2007
    ..This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success...
  47. pmc Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy
    Yu Ping Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Sci Rep 3:2375. 2013
    ..JAK inhibitors reversed the macrophage-induced antiviral state. This study points to a new role for tumor-associated macrophages in the induction of a constitutive antiviral state that shields tumors from viral attack. ..
  48. pmc Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites
    Arun Ammayappan
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA
    J Virol 87:3217-28. 2013
    ..However, in vivo studies explicitly demonstrated that IRES elements of HRV2 and FMDV severely attenuated the neurovirulence of VSV without perturbing its oncolytic potency...
  49. ncbi request reprint The utility of cells as vehicles for oncolytic virus therapies
    Stephen J Russell
    Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Opin Mol Ther 10:380-6. 2008
    ..Aside from their virus chaperoning capabilities, certain carrier cell types may exert additional antitumor activities that operate in synergy with the oncolytic virus infection to mediate tumor regression...
  50. pmc Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari
    Toshie Sakuma
    Department of Molecular Medicine, Mayo Clinic, Guggenheim 18 11c, 200 First Street, SW, Rochester, MN 55905, USA
    J Virol 85:1205-13. 2011
    ..These data support the use of Mus pahari as a model for XMRV pathogenesis and as a platform for vaccine and drug development against this potential human pathogen...
  51. ncbi request reprint Rescue and propagation of fully retargeted oncolytic measles viruses
    Takafumi Nakamura
    Nat Biotechnol 23:209-14. 2005
    ..These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses...
  52. pmc In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46
    Hongjie Wang
    Division of Medical Genetics, University of Washington, Seattle, Washington 98195, USA
    J Virol 82:10567-79. 2008
    ..We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection...

Research Grants8

  1. Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies
    Kah Whye Peng; Fiscal Year: 2007
    ..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..
  2. 4th International Conference on Oncolytic Viruses as Cancer Therapeutics
    Kah Whye Peng; Fiscal Year: 2007
    ..It also provides a forum for trainees to present their work and obtain constructive feedback from senior scientists. This provides an important training ground for tomorrow's scientists. ..
  3. Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies
    Kah Whye Peng; Fiscal Year: 2009
    ..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..
  4. Enhancing localization of therapeutic viruses and cells to tumor sites
    Kah Whye Peng; Fiscal Year: 2010
    ..This grant seeks to improve the tumor localization of measles viruses and virus infected cell carriers by adding vascular binding motifs on their surfaces to enhance their attachment/arrest at tumor neovessels and tumor sites. ..
  5. Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies
    Kah Whye Peng; Fiscal Year: 2010
    ..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..